Project description
Novel drug combination treatment for tuberculosis
Tuberculosis (TB) is still the world's most deadly infectious disease, and multidrug-resistant TB poses a serious threat to global health. Treatment options are limited and often associated with many adverse effects from the drugs. The overall objective of the EU-funded RespiriTB project is to find new drug candidates for efficient combination treatment against TB and multidrug-resistant TB. The drug combination will target the energy metabolism of Mycobacterium tuberculosis (Mtb), using recently discovered inhibitors of the Mtb respiratory pathway. It will also target host factors that are essential for the intracellular survival of Mtb. The project presents a comprehensive plan to find novel strategies to combat TB, shorten treatment time and reduce incidences of drug resistance.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
Programme(s)
Funding Scheme
IMI2-RIA - Research and Innovation actionCoordinator
2333 ZA Leiden
Netherlands
See on map
Participants (8)
2311 EZ Leiden
See on map
2000 Antwerpen
See on map
75006 Paris
See on map
1090 Wien
See on map
1165 Kobenhavn
See on map
2340 Beerse
See on map
93230 Romainville
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1391 JM Abcoude
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.